NCT07124221 - A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets | Biotech Hunter

Enrollment

382

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

November 21, 2026

Study Completion Date

December 30, 2026

Conditions

Hyperprolactinemia

Interventions

DRUG

Cabergoline tablets

Cabergoline tablets will be administered for 14 weeks.The allowed dose range is from 0.25 mg (1 tablet) QW to 1mg (4 tablets) QW. Dosage adjustments are made based on the serum PRL level.

DRUG

Bromocriptine mesylate tablets

Bromocriptine mesylate tablets was administered for 14 weeks.The dose is 1.25 mg (0.5 tablet) QD to 7.5mg 3 tablets) QD. Dosage adjustments are made based on the serum PRL level.

Trial Locations (1)

100730

RECRUITING

Peking Union Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY